Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T Cell in Newly Diagnosed High-Risk T-LBL/ALL
NCT07476027Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Apr 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CD7-CAR T cells in T-lymphoblastic lymphoma (T-LBL) and acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Remission Rate at 28 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CD7-CAR T cells
03
Conditions
T-lymphoblastic lymphoma (T-LBL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07476027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476027.